The expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients.
OBJECTIVE
Little is known about the incidence of hepatitis B virus (HBV) infection in Hodgkin's lymphoma patients. This study was to evaluate the impact of HBV infection on the survival of Hodgkin's lymphoma patient.


METHODS
Clinical data of 120 Hodgkin's lymphoma patients treated at the Sun Yat-sen University Cancer Center between January 2004 and October 2007 were collected. The impact of prognostic factors including HBV infection on survival was examined by univariate and multivariate analyses. A log-rank test was used for univariate analysis and the Cox proportional hazards regression model was used for multivariate analysis.


RESULTS
Of the 120 patients, 18 (15.0%) were hepatitis B virus surface antigen HBsAg-positive. The HBsAg-positive patients had lower 5-year survival rate than did the HBsAg-negative ones (66.9% vs. 91.3%, P = 0.006). When the patients were divided into early-stage (I + II) and advanced-stage (III + IV) groups, the 5-year survival rate was significantly different between the HBsAg-positive and -negative patients in early-stage group (64.8% vs. 96.0%, P < 0.001), while not significantly different in advanced-stage group (75.0% vs. 84.8%, P = 0.667). Both univariate and multivariate analyses showed that radiotherapy and HBV infection were independent prognosis factors for the patients with early-stage Hodgkin's lymphoma (P = 0.006 and 0.014, respectively).


CONCLUSIONS
The incidence of HBV infection is similar between Hodgkin's lymphoma patients and normal population. HBV infection is an independent prognosis factor for survival in the patients with early-stage Hodgkin's lymphoma.
Qiu
Miao-Zhen
MZ
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P. R. China.
Ruan
Dan-Yun
DY
Wang
Zhi-Qiang
ZQ
Luo
Hui-Yan
HY
Teng
Kai-Yuan
KY
Xia
Zhong-Jun
ZJ
Lu
Yue
Y
Huang
Hui-Qiang
HQ
Jiang
Wen-Qi
WQ
Xu
Rui-Hua
RH
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006509:Hepatitis B / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000821:virology*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D015996:Survival Rate
D006514:Hepatitis B Surface Antigens